复发难治性恶性脑膜瘤3例抗血管生成治疗临床分析
发布时间：2018-12-11 15:55
【摘要】：目的探讨复发难治性恶性脑膜瘤的抗血管生成治疗疗效。方法回顾性分析复发难治性恶性脑膜瘤使用抗血管生成药物贝伐珠单抗治疗的3例病例临床资料。结果 3例患者使用贝伐珠单抗后MRI均可见到T2 FLAIR相水肿范围缩小,2例患者增强病灶稳定,1例患者缩小。3例患者临床症状均有缓解,无疾病进展时间分别为2.5、5、7个月。结论贝伐珠单抗使用于常规治疗后复发难治性的恶性脑膜瘤大部分患者可获得临床症状缓解,影像上肿瘤控制,但控制时间有限,难达到临床治愈。
[Abstract]:Objective to investigate the effect of anti-angiogenesis in recurrent refractory malignant meningioma. Methods the clinical data of 3 patients with refractory malignant meningioma treated with antiangiogenic drug bevacizumab were retrospectively analyzed. Results after the use of bevacizumab in 3 patients, the range of T2 FLAIR edema was reduced in MRI, the enhancement focus was stable in 2 patients, and the clinical symptoms were reduced in 1 patient. The clinical symptoms of 3 patients were relieved, and the time of no disease progression was 2. 5%, respectively. Seven months. Conclusion bevacizumab can be used in most patients with recurrent and refractory malignant meningioma after conventional therapy. The clinical symptoms can be alleviated and the tumor can be controlled on image, but the control time is limited and it is difficult to be cured clinically.
【作者单位】： 广东三九脑科医院肿瘤综合治疗中心;
【分类号】：R739.45
[Abstract]:Objective to investigate the effect of anti-angiogenesis in recurrent refractory malignant meningioma. Methods the clinical data of 3 patients with refractory malignant meningioma treated with antiangiogenic drug bevacizumab were retrospectively analyzed. Results after the use of bevacizumab in 3 patients, the range of T2 FLAIR edema was reduced in MRI, the enhancement focus was stable in 2 patients, and the clinical symptoms were reduced in 1 patient. The clinical symptoms of 3 patients were relieved, and the time of no disease progression was 2. 5%, respectively. Seven months. Conclusion bevacizumab can be used in most patients with recurrent and refractory malignant meningioma after conventional therapy. The clinical symptoms can be alleviated and the tumor can be controlled on image, but the control time is limited and it is difficult to be cured clinically.
【作者单位】： 广东三九脑科医院肿瘤综合治疗中心;
【分类号】：R739.45
【相似文献】
相关期刊论文 前10条
1 吴南宁,梁树立,彭林,漆松涛;恶性脑膜瘤的治疗及预后(附3例报告)[J];第一军医大学学报;2000年01期
2 公茂青,王运杰,吴杰;良恶性脑膜瘤T淋巴细胞Ag-NORs表达活性的研究[J];中华神经外科杂志;2001年06期
3 孙金龙,于华强,魏麟,庞琦,张庆林,鲍秀峰,孙炜;恶性脑膜瘤的临床诊断及治疗[J];山东大学学报(医学版);2002年02期
4 胡波,常义,刘宏毅,黄庆玖,张平;恶性脑膜瘤的临床和病理(附12例报告)[J];中国临床神经外科杂志;2002年01期
5 张龙,梅良奎,汪新华,宋莲淑;恶性脑膜瘤颅外转移一例[J];中华神经外科杂志;2003年04期
6 王，
本文编号：2372817
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2372817.html
